Epicutis announced the launch of Hydrobiome Serum, positioning the product as a professional skincare treatment built around a patented TCP molecule.
The company reports a double-blind, placebo-controlled study conducted by Princeton Consumer Research (N=48, 8 weeks) in which subjects using the TCP formulation showed a 77% improvement in overall skin appearance from baseline versus 56% in a comparator group and no measurable improvement in the vehicle control, and the company claims no participants on TCP reported irritation, dryness, or discomfort.
According to the company, Hydrobiome Serum pairs TCP with sodium tocopheryl phosphate (TPNa) and is intended to modulate membrane lipid signaling to support barrier integrity, hydration balance, and reduction of visible redness without broadly suppressing immune activity.
The product is described as available exclusively through licensed aesthetic professionals, dermatology practices, and accredited med-spa partners, consistent with Epicutis’ professional-channel strategy.
The technology is linked to Signum Biosciences’ patented isoprenyl cysteine compounds, and all claims reference the Princeton Consumer Research clinical data on file.
